The company is a commercialized biomedical high-tech company. It was co-founded in 2015 by Dr. Cui Jisong, who has rich experience in new drug development and enterprise management, and Academician Shi Yigong, a world-famous structural biologist. We develop innovative drugs for patients with malignant tumors and autoimmune diseases, so that innovative results can benefit more patients. The company is a high-tech innovative biomedical enterprise with excellent independent research and development capabilities as the core driving force. It has comprehensive R&D, production and commercialization capabilities, focuses on fields such as tumors and autoimmune diseases where there are huge unmet clinical needs, and develops first-of-its-kind or best-in-class drugs with breakthrough potential in the global market. Main products: obutinib, ICP-B04, ICP-248, ICP-B02, ICP-490, ICP-B05, ICP-332, ICP-488, IL-17 small molecule,, ICP-B794, etc. ICP-723 ICP-189